Rapid analysis of mitochondrial DNA depletion by fluorescence in situ hybridization and immunocytochemistry: Potential strategies for HIV therapeutic monitoring

Journal of Histochemistry and Cytochemistry

Volumn 52, Issue 8, 2004, Pages 1011-1018

  Janes, Michael S ^a   Hanson, Bonnie J ^a   Hill, Dani M ^a   Buller, Gayle M ^a   Agnew, Jakyoung Y ^a   Sherwood, Steven W ^a   Cox, W Gregory ^a   Yamagata, Kunihiro ^b   Capaldi, Roderick A ^b  

^a MOLECULAR PROBES INC   (United States)

^b UNIVERSITY OF OREGON   (United States)

Author keywords

AIDS; Cytochrome c oxidase; FISH; HIV; Immunocytochemistry; Mitochondria; Mitochondrial disease; Mitochondrial DNA; Nucleoside reverse; Oxidative phosphorylation; Transcriptase inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; DNA DIRECTED DNA POLYMERASE GAMMA; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ANALYTIC METHOD; ARTICLE; CELL POPULATION; CONTROLLED STUDY; ENZYME INHIBITION; ERADICATION THERAPY; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCYTOCHEMISTRY; LONG TERM CARE; MICROSCOPY; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL TOXICITY; MONITORING; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS;

CELL LINE; DNA, MITOCHONDRIAL; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; ZALCITABINE;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 3242754267     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.3A6209.2004     Document Type: Article

References (29)

1. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, et al. (1981) Sequence and organization of the human mitochondrial genome. Nature 290:457-465
2. Brinkman K, Kakuda TN (2000) Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis 13:5-11
3. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356:1423-1430
4. Carrozzo R, Bornstein B, Lucioli S, Campos Y, de la Pena P, Petit N, Dionisi-Vici C, et al. (2003) Mutation analysis in 16 patients with mtDNA depletion. Hum Mutat 21:453-454
5. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, Schaeffer A, et al. (1999) Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 30:156-160
6. Cossarizza A (2003) Tests for mitochondrial function and DNA: potentials and pitfalls. Curr Opin Infect Dis 16:5-10
7. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, et al. (2002) Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346:811-820
8. Elpeleg O, Mandel H, Saada A (2002) Depletion of the other genome-mitochondrial DNA depletion syndromes in humans. J Mol Med 80:389-396
9. Feng JY, Johnson AA, Johnson KA, Anderson KS (2001) Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 276:23832-23837
10. Fosslien E (2001) Mitochondrial medicine-molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 31:25-67
11. Gourlain K, Amellal B, Ait Arkoub Z, Dupin N, Katlama C, Calvez V (2003) Quantitative analysis of human mitochondrial DNA using a real-time PCR assay. HIV Med 4:287-292
12. Haugland RP (2000) Antibody conjugates for cell biology. In Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz J, Yamada KM, eds. Current Protocols in Cell Biology. New York, John Wiley & Son, 16.5.1-16.5.22
13. Hellerstein MK (2003) Turnover of adipose componentsand mitochondrial DNA in humans: kinetic biomarkers for human immunodeficiency virus-associated lipodystrophy and mitochondrial toxicity. Clin Infect Dis 37(suppl 2):S52-61
14. Kukhanova M, Li X, Chen SH, King I, Doyle T, Prusoff W, Cheng YC (1998) Interaction of beta-L-2′,3′-dideoxy-2′,3′-didehydro-5- fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: implications for human immunodeficiency virus drug design. Mol Pharmacol 53:801-807
15. Lewis W (2003) Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy. Prog Cardiovasc Dis 45:305-318
16. Lim SE, Copeland WC (2001) Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 276:23616-23623
17. 0 human fibroblasts: a comparison of subunit proteins in normal fibroblasts treated with ethidium bromide and fibroblasts from a patient with mtDNA depletion syndrome. Biochim Biophys Acta 1362:145-159
18. Moyle G (2000) Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22:911-936
19. Petit C, Mathez D, Barthelemy C, Leste-Lasserre T, Naviaux RK, Sonigo P, Leibowitch J (2003) Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion. J Acquir Immune Defic Syndr 33:461-469
20. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, et al. (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581-585
21. Sastre J, Pallardo FV, Vina J (2003) The role of mitochondrial oxidative stress in aging. Free Radic Biol Med 35:1-8
22. Schapira AH (2002) Primary and secondary defects of the mitochondrial respiratory chain. J Inherit Metab Dis 3:207-214
23. Scheffler I (1999) Mitochondria. New York, John Wiley & Sons
24. Schon EA, Bonilla E, DiMauro S (1997) Mitochondrial DNA mutations and pathogenesis. Bioenerg Biomembr 29:131-149
25. Taanman JW (1999) The mitochondrial genome: structure, transcription, translation and replication. Biochim Biophys Acta 1410:103-123
26. Taanman JW, Bodnar AG, Cooper JM, Morris AA, Clayton PT, Leonard JV, Schapira AH (1997) Molecular mechanisms in mitochondrial DNA depletion syndrome. Hum Mol Genet 6:935-942
27. Temesgen Z (2001) Current status of antiretroviral therapies. Expert Opin Pharmacother 2:1239-1246
28. Walker UA (2003) Update on mitochondrial toxicity: where are we now? J HIV Ther 8:32-35
29. Yamagata K, Muro K, Usui J, Hagiwara M, Kai H, Arakawa Y, Shimizu Y, et al. (2002) Mitochondrial DNA mutations in focal segmental glomerulosclerosis lesions. J Am Soc Nephrol 13:1816-1823